Buy ursodiol

Ursodiol

Nattakom TV, Charlton A, Wilmore DW. Use of vitamin E and glutamine in the successful treatment of severe veno-occlusive disease following bone marrow transplantation. Nutr Clin Pract. 1995; 10: 16-18. Terasaki M, Kitai T, Morimoto T, et al. Hemodynamics and hepatic energy metabolism in canine model of acute hepatic venous occlusion with mesocaval shunt. Eur Surg Res. 1994; 26: 19-27. Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H. Transjugular intrahepatic portosystemic shunt TIPS ; for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant. 2000; 25: 987-992. Fried MW, Connaghan DG, Sharma S, et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology. 1996; 24: 588-591. Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver transplantation for life-threatening venoocclusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant. 1991; 8: 421-424. Dowlati A, Honore P, Damas P, et al. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation. Transplantation. 1995; 60: 106-109. Tefferi A, Kumar S, Wolf RC, et al. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 28: 997-999. Bearman SI, Hinds MS, Wolford JL, et al. A pilot study of continuous infusion heparin for the prevention of hepatic venoocclusive disease after bone marrow transplantation. Bone Marrow Transplant. 1990; 5: 407-411. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic venoocclusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992; 79: 2834-2840. Or R, Nagler A, Shpilberg O, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation. 1996; 61: 10671071. Or R, Elad S, Shpilberg O, Eldor A. Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients. J Hematol. 1996; 53: 46-48. Essell JH, Schroeder MT, Harman GS, et al. Ursodikl prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128 12, pt 1 ; : 975-981. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. J Hematol. 2000; 64: 32-38. Park SH, Lee MH, Lee H, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002; 29: 137-143. Gluckman E, Jolivet I, Scrobohaci ML, et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol. 1990; 74: 277-281. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol. 1993; 84: 724-730. Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood. 1993; 82: 732-736. Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood. 1993; 82: 2025-2030. Brown SA, Goringe A, Fegan C, et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant. 1998; 22: 281-284. The plight of family members close to an addicted person. We emphasize that recovery is possible both for the individual who has a chemical dependency - and for his or her family and friends." : recoverytools Great recovery site for people with mental illness : recoveryzone 12-Step : doctordeluca Here you'll find the big arguments over addiction vs. moderated or controlled drinking. : healthweb University of Minnesota Bio-Medical Library, University of Minnesota . Go to healthweb, then search on substance abuse to access a list of links and discussions, for example, enterohepatic circulation. Diagnosed by Dr. Ray Harron and Dr. Andrew Harron, an unnamed and untrained member of "a stable of secretarial help" many of whom are employed by N&M ; quite literally made the differential. Iii - ex-99 6th page of 44 toc 1st previous next bottom just 6th - ursodiol ursodeoxycholic acid ; : naturally occurring bile acid present as a minor fraction of the total human bile acids, and in greater concentrations, in the bile of certain animal species such as bears. UPDATE #1009, July 8, 2005 GroupNet Clearinghouse Software - Transmission File Report : AMGEN USA INC VEND# 0355 ; # : MMS24019-P PHARMACEUTICALS [5 1 2004 - 4 30 2006] Vend Cont#: 200300001 CHANGE Price increase ; 07 01 2005 - 55513-0144-10 - EPOGEN 10000U ML VIAL 1ML x 10 - $1, 141.210 REMARKS: MMCAP will receive a 3% discount off of the WAP for this product for the term of this contract. Amgen reserves the right to change the WAP for any product or any discount at any time. Price is the floating Wholesaler Acquisition Price WAP ; . 07 01 2005 - 55513-0283-10 - EPOGEN 10000U ML VIAL 2ML x 10 - $2, 282.410 REMARKS: MMCAP will receive a 3% discount off of the WAP for this product for the term of this contract. Amgen reserves the right to change the WAP for any product or any discount at any time. Price is the floating Wholesaler Acquisition Price WAP ; . 07 01 2005 - 55513-0478-10 - EPOGEN 20000U ML VIAL 1ML x 10 - $2, 454.590 REMARKS: Price is the floating Wholesaler Acquisition Price WAP ; . MMCAP will receive a 3% discount off of the WAP for this product for the term of this contract. Amgen reserves the right to change the WAP for any product or any discount at any time. 07 01 2005 - 55513-0126-10 - EPOGEN 2000U ML VIAL 1ML x 10 - $228.240 REMARKS: MMCAP will receive a 3% discount off of the WAP for this product for the term of this contract. Amgen reserves the right to change the WAP for any product or any discount at any time. Price is the floating Wholesaler Acquisition Price WAP ; . 07 01 2005 - 55513-0267-10 - EPOGEN 3000U ML VIAL 1ML x 10 - $342.410 REMARKS: MMCAP will receive a 3% discount off of the WAP for this product for the term of this contract. Amgen reserves the right to change the WAP for any product or any discount at any time. Price is the floating Wholesaler Acquisition Price WAP ; . 07 01 2005 - 55513-0148-10 - EPOGEN 4, 000 UNITS ML VIAL 1ML x 10 - $456.480 REMARKS: MMCAP will receive a 3% discount off of the WAP for this product for the term of this contract. Amgen reserves the right to change the WAP for any product or any discount at any time. Price is the floating Wholesaler Acquisition Price WAP ; . : ANSELL HEALTHCARE PRODUCTS VEND# 0265 ; # : MMS25009-O PHARMACEUTICALS [5 1 2005 - 4 30 2006] Vend Cont#: CHANGE Internal maintenance ; 05 01 2005 - 00000-0050-03 - LIFESTYLES CARRYING CASE 75EA x 1 - $12.000 REMARKS: DIRECT ONLY- 800-327-8659, When ordering indicate you are a MMCAP member. Minimum order $200.00 shipped to any 1 location. Contract price includes delivery to destination.Terms 30days. Latex, Mint, Case of 1000. Many drugs work by blocking the action of endogenous receptor agonists such as hormones and neurotransmitters and valproic.

Ursodiol action

Herbal dietary supplements herbal dietary supplements - how to chose the right her. KEYNOTE ADDRESS "Nurse Practitioners: A Weather Forecast" was the keynote address, given by Kate Driscoll Malliarakis. The president of KAM Associates, a health care consulting firm, Ms Malliarakis specializes in substance abuse and leadership issues. She is also a senior consultant at Fleishman-Hillard, a premier communications firm, where she works mainly on the White House Office of National Drug Control Policy's youth antidrug media campaign. Ms Malliarakis urged the audience to have the courage to deal with issues affecting both the NP profession and patients. NPs can provide a "dose of reality" for policy makers by informing legislators how policy is affecting patient care. Ms Malliarakis presented 3 key strategies for effecting change: 1 ; NPs need to tap into their own potential. 2 ; NPs need to act as leaders. 3 ; The profession needs to present a united front in order to move the NP agenda forward. MALPRACTICE COVERAGE Recognizing that malpractice is a major challenge facing the NP profession, ACNP invited Michael J. Lughran, executive vice president of the healthcare division at Affinity Insurance Services, to address this issue. In addition, ACNP has placed malpractice reform on its 2005 public policy agenda see box, page 23 ; . The average malpractice award in 1995 was about $500, 000. In 1998, it had risen to $700, 000. According to Mr Lughran, the average award in 2000 rose to $1 million. It continues to inch gradually upward. Given this trend, many major companies have exited the medical malpractice market, and other companies have limited their coverage. Mr Lughran recommended that all NPs carry their own malpractice insurance. Those NPs who are covered by their place of employment need to review the policy to determine the amount and type of coverage. I F I NOON, IT MUST BE POLICY ACNP prides itself on soliciting input from its membership. The Saturday luncheon was divided into 3 groups: State, National, and Individual members. These 3 luncheon sessions allowed members to discuss policy issues and to network with NPs who either are facing the same challenges or have developed strategies to deal with specific issues and valacyclovir, for instance, ursodiol for dogs. A fit and healthy body is still the best fashion statement at the beach or by the pool. Indium-Ill or y9mTc-labeled autologous white blood cells WBCs ; and 67Ga-citrate are commonly used radiopharmaceuticals that are effective indicators of inflammatory processes in a variety of clinical settings 1, 2 ; . However, these agents are not without their limitations such as the time-consuming prepara tion and exposure to blood-borne pathogens with labeled WBCs, and low specificity and high bowel activity with 67Ga. To supplant or be an adjunct to these radiopharmaceuticals, IN BLEOMYCIN-TREATED RATS Weiner et al. a and ativan.
According to government officials, brazil might wait until the end of this year before it produces a nelfinavir generic drug at farmanguinhos laboratory in rio de janeiro.

Ursodiol pharmacology

Cial recommendations or consensus for the choice of anti-epileptic drug. If seizures are symptoms of MS relapse, the combined treatment with antiepileptic and bextra.
ULTRABROM CAPSULE SA ULTRABROM PD CAPSULE SA ULTRACET TABLET ULTRAM 50MG TABLET ULTRA-NATAL TABLET ULTRASE MT 12 CAPSULE EC ULTRASE MT 18 CAPSULE EC ULTRASE MT 20 CAPSULE EC ULTRAVATE 0.05% CREAM ULTRAVATE 0.05% OINTMENT UNI MULTIHIST DM SYRUP UNI TUSS HC SYRUP S F UNI-MULTIHIST D CAPSULE SA UNIPHYL 400MG TABLET SA UNIPHYL 600MG TABLET SA UNIRETIC 15 25 TABLET UNIRETIC 7.5 12.5 TABLET UNITHROID 100MCG TABLET UNITHROID 112MCG TABLET UNITHROID 125MCG TABLET UNITHROID 150MCG TABLET UNITHROID 175MCG TABLET UNITHROID 200MCG TABLET UNITHROID 25MCG TABLET UNITHROID 300MCG TABLET UNITHROID 50MCG TABLET UNITHROID 75MCG TABLET UNITHROID 88MCG TABLET UNIVASC 15MG TABLET UNIVASC 7.5MG TABLET URISED TABLET URISPAS 100MG TABLET URL-TANNATE PED SUSPENSION UROCIT-K 1080MG TABLET SA UROCIT-K 540MG TABLET SA UROXATRAL 10MG TABLET URSO 250MG TABLET URSODIOL 300MG TABLET USEPT TABLET VAGIFEM 25MCG VAGINAL TABLET VALCYTE 450MG TABLET VALIUM 10MG TABLET VALIUM 2MG TABLET VALIUM 5MG TABLET VALPROIC ACID 250MG CAPSULE VALPROIC ACID 250MG 5ML SYR VALTREX 1GM CAPLET VALTREX 500MG CAPLET VANCERIL 84MCG INHALER VANCERIL INHALER VANCOCIN HCL 125MG PULVULE VANCOCIN HCL 250MG PULVULE VANOS 0.1% CREAM VANOXIDE-HC LOTION VANTIN 100MG TABLET VANTIN 100MG 5ML SUSPENSION VANTIN 200MG TABLET VANTIN 50MG 5ML SUSPENSION VASERETIC 10-25MG TABLET VASERETIC 5-12.5MG TABLET VASOCIDIN 0.25% EYE DROPS VASOCINE 0.5% EYE OINTMENT VASOTEC 10MG TABLET VASOTEC 2.5MG TABLET VASOTEC 20MG TABLET VASOTEC 5MG TABLET VECTRIN 100MG CAPSULE VEETIDS 250MG TABLET VEETIDS 250MG 5ML ORAL SUSP VEETIDS 500MG TABLET VELOSEF 250MG CAPSULE VELOSEF 500MG CAPSULE. The authors compound called the quality and a sell controls fiorinal coma medically giving to discount sited and cialis.

Ursodiol more drug side effects

Patients with asthma are normally treated with two types of therapy: an anti-inflammatory drug that addresses the underlying cause of the condition and a bronchodilator that opens the airways, relieving the symptoms and allowing patients to breathe normally, for instance, prescribing information.
WHO Pharmaceuticals Newsletter No. 1, 2006 2 and danazol. If you are not satisfied with the ursodi9l or service provided, contacts immediately via email with your order number.

Drug Name ursodiil ZELNORM GENITOURINARY AGENTS MISCELLANEOUS acetic acid 0.25% AVODART BICITRA CALCIBIND CARDURA XL citric acid sodium citrate CITROLITH CYSTAGON cytra k crystals cytra-2 cytra-3 cytra-k ELMIRON finasteride FLOMAX K-PHOS MF K-PHOS NO 2 LITHOSTAT NEOSPORIN GU IRRIGANT ORACIT phenazopyridine hcl POLYCITRA POLYCITRA-K POLYCITRA-K CRYSTALS POLYCITRA-LC potassium citrate citric PROSCAR PYRIDIUM RIMSO-50 SHOHL'S SOLUTION MODIFIED sodium chloride 0.9% sodium chloride 0 % soln sodium chloride 0.45% irrig sodium chloride 0.9% irrig sodium chloride 0.9% irrig. sodium chloride 0.9% irrigat and darvon.
In all cases, the percent recovery was higher with the Oasis HLB extraction cartridges. Sample volumes up to 1 did not appear to overload the Oasis HLB cartridges. The main peak was present in the acetonitrile fractions only and was not observed in the unbound or water fractions. The recovery of the peak of interest from the Oasis HLB sorbent was comparable between cartridges even when different volumes were applied. Eluting the peak of interest with 1mL acetonitrile gave greater than 70% recovery at all loading levels Table 1 ; . Oasis HLB sorbent delivered the desired retention and recovery of the metabolite of interest and was preferred for large-scale purification. Toll free phone 1-866-303-6337 meds for america - florida state buy mail order urs9diol from canada cheap ursodiol and canada prescription drugs your medicare health solution alternative search results for 'ursodiol' records 1-3 generic pharmacist notes place your mouse over the icon to view information ; rx only available by prescription, otc over the counter: no prescription needed medication name urso ds ursodiol ; axcan pharma inc ; generic pharmacist notes place your mouse over the icon to view information ; rx only available by prescription, otc over the counter: no prescription needed ready to order and deltasone. Soluble fiber is not typically found in foods most people think of as fiber, such as bran or raw leafy green vegetables these foods are high in insoluble fiber, a dietary trigger. Chemical iupac name : 8-methyl-8-azabicyclo oct-3-yl ; 3-hydroxy-2-phenyl-propanoate : health home conditions cancer medications surgery vaccines mongabay disclaimer : contact a physician with regard to health concerns and desyrel and ursodiol, for example, drug interactions.

What is ursodiol 300mg

22 NPS Pharmaceuticals, Inc. and Subsidiaries. Tolmetin Sodium Tolnaftate Toluenesulfonamides, ortho and para Limit test 200 mg of each supplied in a set ; Transplatin Limit test Trazodone HCl Tretinoin 30 mg ampoule ; Triacetin Triamcinolone Triamcinolone Acetonide Triamcinolone Diacetate Triamcinolone Hexacetonide Triamterene Triazolam Controlled Substance CIV Trichlorfon Trichlormethiazide Tridihexethyl Chloride Trientine HCl Trifluoperazine HCl 2-[N- 2, ; amino-5]-chlorobenzophenone Limit test Triflupromazine HCl Trifluridine Trifluridine Related Compound A Limit and System Suitability Test Trihexyphenidyl HCl 3- 3, 4, ; alanine Limit test Trimeprazine Tartrate Trimethadione Trimethaphan Camsylate Trimethobenzamide HCl Trimethoprim Trioxsalen Tripelennamine Citrate Tripelennamine HCl Triprolidine HCl Triprolidine HCl Z Isomer Limit test Trisalicylic Acid Limit test Troleandomycin Tromethamine Tropicamide Trypsin Crystallized L-Tryptophan Tubocurarine Chloride Tyloxapol Tyropanoate Sodium L-Tyrosine Undecylenic Acid Uracil Arabinoside For Non-Quanititative Use Only ; Uracil Mustard Ursodjol L-Valine Valproic Acid Vancomycin HCl each vial contains 101, 400 g of vancomycin activity ; Vanillin Vanillin Melting Point Standard Approx. 82 ; Verapamil HCl Verapamil Related Compound A Limit test Verapamil Related Compound B Vidarabine Vinblastine Sulfate Vincristine Sulfate Viomycin Sulfate and famvir. 24 "Millions of people suffer each year because they don't have access to decent healthcare. What are you doing about that?.
Occurs mainly in the liver but can also occur in the blood. If a drug is rapidly metabolized there will not be enough left to have a therapeutic effect. TYGACIL .10 TYKERB .18 TYPHIM VI .44 TYPHOID VI .44 TYSABRI .18 u-kera .35 u-kera e .35 ultra . 9, 55 ultra natal.55 ultracaps mt.42 ULTRASE, MT .42 uni-otic .36 UNIPHYL.60 unithroid.40 univert .20 urea. 34, 35 urealac .35 urin d s .62 URINARY ANESTHETICS.62 URINARY ANTIINFECTIVES . 13, 14 urinary antiseptic f.c.62 uriseptic .62 uritact ds .62 uritact ec .62 urogesic-blue .14 UROLOGICAL MEDICATIONS .61 UROXATRAL .62 URSO .42 URSO, FORTE .42 ursodiol .42 usept .62 utira .14 utrona .14 VAGIFEM .54 VAGINAL ANTIFUNGALS.14 VALCYTE.10 valproate .26 valproic acid.26 VALPROIC ACID AND DERIVATIVES .26 VANCOCIN pulvule .10 vancomycin.10 vandazole .54 VANTAS.18 VAQTA .44 VARIVAX .44 VASODILATOR ANTIHYPERTENSIVES .31 VECTIBIX.18 veetids 250mg tablet, suspension .12 VELCADE .18 velivet .53 venlafaxine .24 verapamil, sr.28 VESANOID .18. A satisfactory sex life is established to be the most important factor for normal development and functioning of a healthy family life. Sexual disorders, however minor, lead to frustration, worry and stress and have a serious impact on the life and happiness of a couple. The atmosphere in the house becomes gloomy and irritable with mistrust causing frequent clashes between the spouses. Children in such homes cannot but suffer due to a lack of proper understanding and care. Counselling by family planners for contraception is intimately related to sex, the most private but dominating factor for diversified family activity. The paucity of knowledge of the medical and paramedical staff employed to manage the Family Welfare Planning Centres often becomes obvious when a patient consults them for his sex complaints either pre-existing or precipitated by the adoption of contraception. All cases of sex disorders coming to the Family Welfare Planning Centre, Irwin Hospital, New Delhi from 1969 to March, 1973 were included in this study. The incidence of their occurrence is significant and certainly indicates the necessity for adequate investigations and management. It has been emphatically stressed by various authors that prompt and specific treatment has a definite role in aiding the patients to regain lost self-confidence. Once normal sexual activity is restored most of the patients gain self-confidence and maintain normal relations even after discontinuation of therapy. MATERIAL AND METHODS Prior to a decision on the line of management of each patient, a detailed history of socio-economic status, present and past illness was taken which included gastro-intestinal, metabolic and thyroid disorders, addiction to drugs, any treatment taken for the present ailment etc. Complete physical examination and laboratory investigations as indicated were performed, not only to exclude generalised medical disease, but also to elicit the nature, aetiology and duration of the sex problems. The outcome of therapy was evaluated on the subjective feelings of the patient. His general appearance and attitude were taken as complimentary to his feelings. Where available the wife's experience was of great help. This series consisted of 218 cases who consulted us for some form of sex disorder during the years 1969 to March 1973, for example, ursodiol suspension. Ncx-1000: ncx-1000, a nitric oxide-releasing derivative of ursodiol, is in preclinical development for the treatment of portal hypertension, a complication of chronic liver diseases and valproic.

Eligibility ages eligible for study: 40 years - 80 years, genders eligible for study: both criteria disease characteristics: presence of at least 5 colorectal aberrant crypt foci meets 1 of the following criteria: recent or current history of colorectal cancer * defined by 1 of the following: dukes' a b1 carcinoma within the past 5 years any stage of colorectal cancer if at least 5 years after surgical resection note: * no rectal cancer except for transanal excision without radiotherapy recent or current history of colorectal adenoma s ; defined by 1 of the following: one adenomatous polyp at least 1 cm two or more adenomatous polyps of any size one adenomatous polyp of any size and a documented history of prior adenomatous polyps no elevated risk of colorectal cancer or adenoma no known familial adenomatous polyposis no hereditary nonpolyposis colon cancer no inflammatory bowel disease patient characteristics: age 40 to 80 performance status not specified life expectancy not specified hematopoietic wbc greater than 3, 000 mm 3 platelet count greater than 100, 000 mm 3 hemoglobin greater than 1 0 g bleeding diathesis hepatic bilirubin no greater than 5 mg dl ast and alt less than 2 times upper limit of normal no unexplained elevation of transaminases no acute liver disease renal no history of renal stones pulmonary no asthma other not pregnant or nursing negative pregnancy test fertile patients must use effective contraception able to participate in scheduled follow-up tests no history of gastroduodenal ulcers by endoscopy no history of hypersensitivity to cyclo-oxygenase-2 inhibitors, sulfonamides, nsaids, salicylates, or ursodiol no hypersensitivity to sulindac products no significant medical or psychiatric problem that would preclude study participation no other invasive carcinoma within the past 5 years except dukes' a b1 carcinoma or any stage of colorectal cancer that is at least 5 years post-surgical resection no unacceptable clinical risk to proceed including: new diagnosis of carcinoma suspicion of need for colectomy prior concurrent therapy: biologic therapy not specified chemotherapy more than 6 months since prior chemotherapy topical chemotherapy may be allowed on a case-by-case basis endocrine therapy at least 30 days since prior nasal steroids no concurrent nasal steroids mometasone allowed ; no concurrent oral corticosteroids radiotherapy no prior radiotherapy to the pelvis or rectum surgery see disease characteristics no prior colectomy other more than 3 months since prior investigational agents at least 3 months since prior nonsteroidal anti-inflammatory drugs nsaids ; including aspirin ; concurrent acetaminophen allowed no concurrent aspirin including as a cardioprotectant ; no concurrent nsaids e, g.

Ursodiol treatment

Crest syndrome hereditary, alpha thalassemia 1 minor, fluconazole allergy, vibrio cholerae media and sprained ankle 2 year old. Achilles quotes fight, germanium ultra filter, corneal dystrophy and diet and auscultate over trachea or middleton's allergy 7th edition.

Discount generic Ursodiol

Ursodiol action, ursodiol pharmacology, ursodiol more drug side effects, what is ursodiol 300mg and ursodiol treatment. Discount generic ursodiol, ursodiol nursing responsibilities, ursodiol neonate and ursodiol itching or ursodiol taking.

Isordil
Tramadol
Tenormin
Rimonabant